FIELD: biotechnology.
SUBSTANCE: variants of a pharmaceutical composition containing an effective amount of an antibody that specifically binds to C5 are proposed for the treatment of a complement-mediated disease or condition that includes excessive or uncontrolled C5 activation, or to enhance the clearance of C5 from plasma. The use of an antibody that specifically binds to C5 is also proposed for the preparation of a medicament for the treatment of a complement-mediated disease or condition that includes excessive or uncontrolled C5 activation, or to enhance the clearance of C5 from plasma. An effective amount of antibody variant that specifically binds to C5 is used in a method for treating an individual with a complement-mediated disease or condition that includes excessive or uncontrolled C5 activation, or a method for enhancing plasma clearance of C5 in a subject.
EFFECT: ensuring the effectiveness of the treatment of complement-mediated disease or condition that includes excessive or uncontrolled C5 activation.
42 cl, 29 dwg, 11 tab, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| COMPOSITION FOR PREVENTION OR TREATMENT OF IL-8-RELATED DISEASES | 2017 |
|
RU2766112C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2019 |
|
RU2789389C2 |
